Fang Liu

Core Replacements in a Potent Series of VEGFR-2 Inhibitors and Their Impact on Potency, Solubility, and hERG.

K. Gunderson, N. Mainolfi, K. Anderson, 2016, ACS medicinal chemistry letters.

Evolution of a New Class of VEGFR-2 Inhibitors from Scaffold Morphing and Redesign.

F. Liu, R. Karki, N. Mainolfi, 2016, ACS medicinal chemistry letters.

Title Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration

J. Sivak, Fupeng Ma, P. Tarsa, 2018 .

Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration.

J. Sivak, B. Jaffee, Fupeng Ma, 2015, Journal of medicinal chemistry.

Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases.

Thomas M. Smith, N. Gradoux, Jian Ding, 2020, Journal of medicinal chemistry.

A small-molecule inhibitor of C5 complement protein

M. Schirle, Mitsunori Kato, G. Michaud, 2019, Nature Chemical Biology.

The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration.

J. Sivak, B. Jaffee, Fupeng Ma, 2018, Journal of medicinal chemistry.